Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer
Gemma A Foulds, Jayakumar Vadakekolathu, Tarek M A Abdel-Fatah, Divya Nagarajan, Stephen Reeder, Catherine Johnson, Simon Hood, Paul M Moseley, Stephen Y T Chan, A Graham Pockley, Sergio Rutella, Stephanie E B McArdle, Gemma A Foulds, Jayakumar Vadakekolathu, Tarek M A Abdel-Fatah, Divya Nagarajan, Stephen Reeder, Catherine Johnson, Simon Hood, Paul M Moseley, Stephen Y T Chan, A Graham Pockley, Sergio Rutella, Stephanie E B McArdle
Abstract
Background: Interactions between the immune system and tumors are highly reciprocal in nature, leading to speculation that tumor recurrence or therapeutic resistance could be influenced or predicted by immune events that manifest locally, but can be detected systemically. Methods: Multi-parameter flow cytometry was used to examine the percentage and phenotype of natural killer (NK) cells, myeloid-derived suppressor cells (MDSCs), monocyte subsets and regulatory T (Treg) cells in the peripheral blood of of 85 patients with breast cancer (50 of whom were assessed before and after one cycle of anthracycline-based chemotherapy), and 23 controls. Transcriptomic profiles of peripheral blood mononuclear cells (PBMCs) in 23 patients were generated using a NanoString gene profiling platform. Results: An increased percentage of immunosuppressive cells such as granulocytic MDSCs, intermediate CD14++CD16+ monocytes and CD127negCD25highFoxP3+ Treg cells was observed in patients with breast cancer, especially patients with stage 3 and 4 disease, regardless of ER status. Following neoadjuvant chemotherapy, B cell numbers decreased significantly, whereas monocyte numbers increased. Although chemotherapy had no effect on the percentage of Treg, MDSC and NK cells, the expression of inhibitory receptors CD85j, LIAR and NKG2A and activating receptors NKp30 and NKp44 on NK cells increased, concomitant with a decreased expression of NKp46 and DNAM-1 activating receptors. Transcriptomic profiling revealed a distinct group of 3 patients in the triple negative breast cancer (TNBC) cohort who expressed high levels of mRNA encoding genes predominantly involved in inflammation. The analysis of a large transcriptomic dataset derived from the tumors of patients with TNBC revealed that the expression of CD163, CXCR4, THBS1 predicted relapse-free survival. Conclusions: The peripheral blood immunome of patients with breast cancer is influenced by the presence and stage of cancer, but not by molecular subtypes. Furthermore, immune profiling coupled with transcriptomic analyses of peripheral blood cells may identify patients with TNBC that are at risk of relapse after chemotherapy.
Keywords: MDSC; NK cells; breast cancer; flow cytometry; immune gene signature; monocytes; nanostring; treg.
Figures
References
- Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. . Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer (2013) 49:1374–403. 10.1016/j.ejca.2012.12.027
- Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. . Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. (2014) 32:2959–66. 10.1200/JCO.2013.55.0491
- Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, et al. . Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat (2012) 132:793–805. 10.1007/s10549-011-1554-7
- Kroemer G, Senovilla L, Galluzzi L, Andre F, Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. Nat Med. (2015) 21:1128–38. 10.1038/nm.3944
- Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. . Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. (2011) 121:2750–67. 10.1172/JCI45014
- Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. . Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. (2010) 28:105–13. 10.1200/JCO.2009.23.7370
- Miyashita M, Sasano H, Tamaki K, Chan M, Hirakawa H, Suzuki A, et al. . Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat (2014) 148:525–34. 10.1007/s10549-014-3197-y
- Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature (2008) 454:436–44. 10.1038/nature07205
- Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. (2002) 169:2756–61. 10.4049/jimmunol.169.5.2756
- Plitas G, Konopacki C, Wu K, Bos PD, Morrow M, Putintseva EV, et al. . Regulatory T cells exhibit distinct features in human breast cancer. Immunity (2016) 45:1122–34. 10.1016/j.immuni.2016.10.032
- Kulkarni MM. Digital multiplexed gene expression analysis using the NanoString nCounter system. Curr Protoc Mol Biol. (2011) Chapter 25:Unit25B 10. 10.1002/0471142727.mb25b10s94
- Cesano A. nCounter((R)) PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA). J Immunother Cancer (2015) 3:42. 10.1186/s40425-015-0088-7
- Strauss L, Bergmann C, Szczepanski MJ, Lang S, Kirkwood JM, Whiteside TL. Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol. (2008) 180:2967–80. 10.4049/jimmunol.180.5.2967
- Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, Whiteside TL. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods (2012) 381:14–22. 10.1016/j.jim.2012.04.004
- Konjevic G, Jurisic V, Spuzic I. Association of NK cell dysfunction with changes in LDH characteristics of peripheral blood lymphocytes (PBL) in breast cancer patients. Breast Cancer Res Treat (2001) 66:255–63. 10.1023/A:1010602822483
- Wijayahadi N, Haron MR, Stanslas J, Yusuf Z. Changes in cellular immunity during chemotherapy for primary breast cancer with anthracycline regimens. J Chemother. (2007) 19:716–23. 10.1179/joc.2007.19.6.716
- Verma R, Foster RE, Horgan K, Mounsey K, Nixon H, Smalle N, et al. . Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res. (2016) 18:10. 10.1186/s13058-015-0669-x
- Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. . An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat (2010) 123:725–31. 10.1007/s10549-009-0674-9
- Verma C, Eremin JM, Robins A, Bennett AJ, Cowley GP, El-Sheemy MA, et al. . Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC. J Transl Med. (2013) 11:16. 10.1186/1479-5876-11-16
- Wang J, Yang J. Identification of CD4(+)CD25(+)CD127(−) regulatory T cells and CD14(+)HLA(−)DR(−)/low myeloid-derived suppressor cells and their roles in the prognosis of breast cancer. Biomed Rep. (2016) 5:208–12. 10.3892/br.2016.694
- Ito T, Hanabuchi S, Wang YH, Park WR, Arima K, Bover L, et al. . Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity (2008) 28:870–80. 10.1016/j.immuni.2008.03.018
- Mohr A, Malhotra R, Mayer G, Gorochov G, Miyara M. Human FOXP3(+) T regulatory cell heterogeneity. Clin Transl Immunol. (2018) 7:e1005. 10.1002/cti2.1005
- Jurisic V, Colovic M. Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma. Med Oncol. (2002) 19:133–9. 10.1385/MO:19:3:133
- Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. . Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity (2009) 30:899–911. 10.1016/j.immuni.2009.03.019
- Kordasti S, Costantini B, Seidl T, Perez Abellan P, Martinez Llordella M, Mclornan D, et al. . Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment. Blood (2016) 128:1193–205. 10.1182/blood-2016-03-703702
- Speigl L, Burow H, Bailur JK, Janssen N, Walter CB, Pawelec G, et al. . CD14+ HLA-DR-/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation. Breast Cancer Res Treat (2018) 168:401–11. 10.1007/s10549-017-4594-9
- Bailur JK, Gueckel B, Derhovanessian E, Pawelec G. Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients. Breast Cancer Res. (2015) 17:34. 10.1186/s13058-015-0541-z
- Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. (2009) 58:49–59. 10.1007/s00262-008-0523-4
- Gonda K, Shibata M, Ohtake T, Matsumoto Y, Tachibana K, Abe N, et al. . Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer. Oncol Lett. (2017) 14:1766–74. 10.3892/ol.2017.6305
- Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, Stauffer JK, et al. . Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci USA. (2009) 106:19455–60. 10.1073/pnas.0909474106
- Rutella S, Filippini P, Bertaina V, Li Pira G, Altomare L, Ceccarelli S, et al. . Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)-alphabeta/CD19-depleted haploidentical stem cell grafts. J Transl Med. (2014) 12:240. 10.1186/s12967-014-0240-z
- Bailur JK, Pawelec G, Hatse S, Brouwers B, Smeets A, Neven P, et al. . Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty. Breast Cancer Res. (2017) 19:20. 10.1186/s13058-017-0813-x
- Feng AL, Zhu JK, Sun JT, Yang MX, Neckenig MR, Wang XW, et al. . CD16+ monocytes in breast cancer patients: expanded by monocyte chemoattractant protein-1 and may be useful for early diagnosis. Clin Exp Immunol. (2011) 164:57–65. 10.1111/j.1365-2249.2011.04321.x
- Dewan MZ, Terunuma H, Takada M, Tanaka Y, Abe H, Sata T, et al. . Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Res Treat (2007) 104:267–75. 10.1007/s10549-006-9416-4
- Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet (2000) 356:1795–9. 10.1016/S0140-6736(00)03231-1
- Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, et al. . Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. (2011) 121:3609–22. 10.1172/JCI45816
- Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, et al. . Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat Med. (2018) 24:986–93. 10.1038/s41591-018-0078-7
Source: PubMed